1. Home
  2. QNRX vs CHEK Comparison

QNRX vs CHEK Comparison

Compare QNRX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNRX
  • CHEK
  • Stock Information
  • Founded
  • QNRX 2018
  • CHEK 2004
  • Country
  • QNRX United States
  • CHEK Israel
  • Employees
  • QNRX 3
  • CHEK N/A
  • Industry
  • QNRX Medical/Dental Instruments
  • CHEK Medical Electronics
  • Sector
  • QNRX Health Care
  • CHEK Health Care
  • Exchange
  • QNRX Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • QNRX 4.8M
  • CHEK 3.9M
  • IPO Year
  • QNRX N/A
  • CHEK 2015
  • Fundamental
  • Price
  • QNRX $8.59
  • CHEK $2.32
  • Analyst Decision
  • QNRX
  • CHEK
  • Analyst Count
  • QNRX 0
  • CHEK 0
  • Target Price
  • QNRX N/A
  • CHEK N/A
  • AVG Volume (30 Days)
  • QNRX 107.3K
  • CHEK 8.7M
  • Earning Date
  • QNRX 11-06-2025
  • CHEK 11-14-2025
  • Dividend Yield
  • QNRX N/A
  • CHEK N/A
  • EPS Growth
  • QNRX N/A
  • CHEK N/A
  • EPS
  • QNRX N/A
  • CHEK N/A
  • Revenue
  • QNRX N/A
  • CHEK N/A
  • Revenue This Year
  • QNRX N/A
  • CHEK N/A
  • Revenue Next Year
  • QNRX N/A
  • CHEK N/A
  • P/E Ratio
  • QNRX N/A
  • CHEK N/A
  • Revenue Growth
  • QNRX N/A
  • CHEK N/A
  • 52 Week Low
  • QNRX $5.01
  • CHEK $0.56
  • 52 Week High
  • QNRX $54.95
  • CHEK $3.13
  • Technical
  • Relative Strength Index (RSI)
  • QNRX 70.88
  • CHEK 84.28
  • Support Level
  • QNRX $7.35
  • CHEK $0.65
  • Resistance Level
  • QNRX $7.79
  • CHEK $3.13
  • Average True Range (ATR)
  • QNRX 0.38
  • CHEK 0.23
  • MACD
  • QNRX 0.13
  • CHEK 0.20
  • Stochastic Oscillator
  • QNRX 46.79
  • CHEK 67.72

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: